- Home
- ANAB vs NRDS Comparison
ANAB vs NRDS Comparison
Compare ANAB & NRDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | NRDS |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANAB | NRDS |
|---|---|---|
| Price | $49.06 | $14.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $59.90 | $15.40 |
| AVG Volume (30 Days) | 503.4K | ★ 893.7K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.93 |
| Revenue | $169,467,000.00 | ★ $795,000,000.00 |
| Revenue This Year | $135.45 | $22.09 |
| Revenue Next Year | N/A | $7.18 |
| P/E Ratio | ★ N/A | $16.09 |
| Revenue Growth | ★ 196.42 | 24.71 |
| 52 Week Low | $12.21 | $7.55 |
| 52 Week High | $48.44 | $16.24 |
Technical Indicators
Market Signals| Indicator | ANAB | NRDS |
|---|---|---|
| Relative Strength Index (RSI) | 76.21 | 52.91 |
| Support Level | $43.92 | $13.58 |
| Resistance Level | $47.86 | $15.13 |
| Average True Range (ATR) | 2.33 | 0.56 |
| MACD | 0.19 | -0.16 |
| Stochastic Oscillator | 98.35 | 36.47 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.